Hypoxia-activated paclitaxel prodrugs enable PD-L1 degradation to potentiate cancer chemo-immunotherapy
Abstract The combination of chemotherapy and immune checkpoint blockade therapy shows great potential in tumor treatment, but their integration remains a great challenge. Herein, hypoxia-responsive prodrugs integrating paclitaxel (PTX) and bromodomain-containing protein 4 inhibitor JQ1 were designed...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BMC
2025-12-01
|
| Reeks: | Journal of Nanobiotechnology |
| Onderwerpen: | |
| Online toegang: | https://doi.org/10.1186/s12951-025-03894-x |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|